High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
CGHS would give robust coverage to pensioners and with new innovations and practices
He is a seasoned business leader with a successful track record of over 26 years across local and area roles within the pharmaceutical industry
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
New material distribution will serve medical device and pharmaceutical packaging manufacturers.
Sotatercept demonstrated significant improvement in exercise capacity and key secondary outcome measures compared to placebo when added to background therapy
Subscribe To Our Newsletter & Stay Updated
